Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Øyvind S Bruland

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Anticancer Research|October 28, 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?Ivar Hompland, Øyvind S Bruland
Anticancer Research|May 17, 2019
Prognostic Impact of Proximal <i>Versus</i> Distal Localization in Extremity Long Bone OsteosarcomasKjetil Berner, Øyvind S Bruland
Clinical Orthopaedics and Related Research|January 22, 2005
TP-3 immunotoxins improve antitumor activity in mice with osteosarcomaMasanori Onda, Øyvind S Bruland, Ira Pastan
Sarcoma|September 29, 2015
Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009Kjetil Berner, Tom Børge Johannesen, Øyvind S Bruland
Anticancer Research|April 12, 2015
Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literatureKjetil Berner, Bodil Bjerkehagen, Øyvind S Bruland, et al.
Cancer Treatment and Research|March 10, 2010
Treatment of osteosarcoma. The Scandinavian Sarcoma Group experienceØyvind S Bruland, Henrik Bauer, Thor Alvegaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 29, 2013
Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapyEspen Rusten, Jan Rødal, Øyvind S Bruland, et al.
Anticancer Research|October 28, 2015
Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative StudyLena Fauske, Hilde Bondevik, Øyvind S Bruland, et al.
Current Radiopharmaceuticals|December 29, 2011
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugatesJostein Dahle, Nasir Abbas, Øyvind S Bruland, et al.
Anticancer Research|January 30, 2022
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal TumoursLena Fauske, Pernille H Wærstad, Ivar Hompland, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Anticancer Research|October 28, 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?Ivar Hompland, Øyvind S Bruland
Anticancer Research|May 17, 2019
Prognostic Impact of Proximal <i>Versus</i> Distal Localization in Extremity Long Bone OsteosarcomasKjetil Berner, Øyvind S Bruland
Clinical Orthopaedics and Related Research|January 22, 2005
TP-3 immunotoxins improve antitumor activity in mice with osteosarcomaMasanori Onda, Øyvind S Bruland, Ira Pastan
Sarcoma|September 29, 2015
Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009Kjetil Berner, Tom Børge Johannesen, Øyvind S Bruland
Anticancer Research|April 12, 2015
Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literatureKjetil Berner, Bodil Bjerkehagen, Øyvind S Bruland, et al.
Cancer Treatment and Research|March 10, 2010
Treatment of osteosarcoma. The Scandinavian Sarcoma Group experienceØyvind S Bruland, Henrik Bauer, Thor Alvegaard, et al.
Acta Oncologica (Stockholm, Sweden)|August 29, 2013
Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapyEspen Rusten, Jan Rødal, Øyvind S Bruland, et al.
Anticancer Research|October 28, 2015
Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative StudyLena Fauske, Hilde Bondevik, Øyvind S Bruland, et al.
Current Radiopharmaceuticals|December 29, 2011
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugatesJostein Dahle, Nasir Abbas, Øyvind S Bruland, et al.
Anticancer Research|January 30, 2022
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal TumoursLena Fauske, Pernille H Wærstad, Ivar Hompland, et al.
Pageof 8